htig
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Apr 18, 2022 (NCT05625477)
Timeline
Indications
Studied for
Mechanism of action
- Tetanus toxinANTAGONIST
tetanus toxin
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06939777 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | China National Pharmaceutical Group |
| NCT06635798 | Phase 3 | Sep 3, 2024 | Government of China, Huazhong University of Science and Technology, Peking University |
| NCT06302374 | Phase 1/Phase 2 (Phase 2) | Mar 4, 2023 | Government of China |
| NCT05625477 | Phase 2 | Apr 18, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Peking University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 2 | 2023 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| China National Pharmaceutical Group | For profit | 1 | 1 | 1 | 2025 |
| Guangzhou Trinomab Biotech Co., Ltd. | Government | 1 | 1 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1